MedTrace Logo

Expanded Access to Tipifarnib

NCT04809233 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-06-29

No results posted yet for this study

Summary

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).

To request access, use Responsible Party contact information provided in this record.

Expanded access for tipifarnib is only available in the United States.

Conditions

  • HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Interventions

DRUG

Tipifarnib

Tipifarnib

Sponsors & Collaborators

  • Kura Oncology, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809233 on ClinicalTrials.gov